Single dose of atezolizumab plus chemotherapy in active psoriasis with advanced non-small cell lung cancer

Introduction Immunotherapy has been recognized as the standard of care in addition to chemotherapy in the treatment of advanced non-small cell lung cancer. Most immunotherapy trials, however, exclude patients with autoimmune disease owing to concerns of disease exacerbation. Case report We report a...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 2022-03, Vol.28 (2), p.471-474
Main Authors: Wong, Pui Yee, How, Soon Hin, Ismail, Irnani, Hassan, Radhiana
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Autoimmune diseases
Carcinoma, Non-Small-Cell Lung - drug therapy
Case reports
Chemotherapy
Clinical trials
Humans
Immunotherapy
Lung cancer
Lung Neoplasms - drug therapy
Monoclonal antibodies
Non-small cell lung carcinoma
Patients
Psoriasis
Psoriasis - drug therapy
Remission
Small cell lung carcinoma
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Immunotherapy has been recognized as the standard of care in addition to chemotherapy in the treatment of advanced non-small cell lung cancer. Most immunotherapy trials, however, exclude patients with autoimmune disease owing to concerns of disease exacerbation. Case report We report a case of a patient with advanced non-small cell lung cancer and underlying active psoriasis who experienced a remarkable response, without developing psoriasis flares, following treatment with a single dose of atezolizumab and first-line chemotherapy. Management and outcome The patient remained asymptomatic 10 months since treatment discontinuation, without disease progression, despite having received only a single dose of atezolizumab and six cycles of chemotherapy. Discussion Little is known about the optimum duration required to achieve a durable response with immunotherapy. Patients with autoimmune disease are commonly excluded from immunotherapy trials owing to a higher risk of autoimmune disease flares or immune-related adverse events. The remarkable outcome observed in this case offers some insights into the possible durable response with limited doses of immunotherapy and a safer approach for administering immunotherapy in patients with autoimmune disease. Initiating chemotherapy to induce remission in active autoimmune disease prior to administering immunotherapy could potentially be an ideal approach that facilitates the use of immunotherapy in this patient population.
ISSN:1078-1552
1477-092X
DOI:10.1177/10781552211038899